文献类型：期刊文献

英文题名：UBA2 as a Prognostic Biomarker and Potential Therapeutic Target in Glioma

作者：Ou, Yuhong[1,2];Luo, Hongtao[2,3];Zhang, Qiuning[2,3];Du, Tianqi[1,2];Liu, Ruifeng[2,3];Wang, Dandan[1,2];Chen, Junru[1,2];Dong, Meng[1,2];Wang, Yuhang[1,2];Yang, Zhen[2,4];Wang, Xiaohu[1,2,3]

第一作者：Ou, Yuhong

通信作者：Wang, XH[1];Wang, XH[2];Wang, XH[3]

机构：[1]Lanzhou Univ, Sch Clin Med 1, Lanzhou 730030, Gansu, Peoples R China;[2]Chinese Acad Sci, Inst Modern Phys, Lanzhou 730030, Gansu, Peoples R China;[3]Univ Chinese Acad Sci, Dept Postgrad, Beijing 100043, Peoples R China;[4]Gansu Univ Chinese Med, Sch Publ Hlth, Lanzhou 730030, Gansu, Peoples R China

第一机构：Lanzhou Univ, Sch Clin Med 1, Lanzhou 730030, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Clin Med 1, Lanzhou 730030, Gansu, Peoples R China;[2]corresponding author), Chinese Acad Sci, Inst Modern Phys, Lanzhou 730030, Gansu, Peoples R China;[3]corresponding author), Univ Chinese Acad Sci, Dept Postgrad, Beijing 100043, Peoples R China.

年份：2024

卷号：29

期号：4

外文期刊名：FRONTIERS IN BIOSCIENCE-LANDMARK

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001222942200005)】；

基金：The study was supported by the National Key Research and Development Program of China (No. 2022YFC2401500) , Science and Technology Plan Project of Chengguan District of Lanzhou (No. 2020-2-2-5) , Talent Innovation and Venture Project of Lanzhou City (No. 2017 -RC -23; 2021 -RC -125; 2020 -RC -113) , China Foundation for International Medical Exchange (No. Z-2017- 24-2108) , Gansu Province Project of Science and Technologies (Grant No. 20JR10RA680) , and the Lanzhou heavy Ion Accelerator High-end user Project (HIR20GY007) .

语种：英文

外文关键词：UBA2; glioma; prognosis; tumor progression; immunity; radiosensitivity

摘要：Background: Gliomas are characterized by aggressive behavior, leading to severe disability and high mortality. Ubiquitin-like modifier activating enzyme 2 (UBA2) is a subunit of the E1-activating enzyme involved in the SUMOylation (SUMO, small ubiquitin-related modifier) of numerous proteins. Although the abnormality of UBA2 is linked to the progression of various tumor types, the role of UBA2 in glioma is still unknown. Methods: A bioinformatic analysis using several public databases was conducted to examine the expression level, clinicopathological correlations, and prognostic significance of UBA2 in glioma. The correlation between UBA2 expression and drug sensitivity in cancers was also explored. Multiple cellular experiments were conducted to validate the role of UBA2 in glioma. Results: Analysis of multiple databases and cellular experiments revealed that UBA2 was overexpressed in glioma tissues and cell lines, respectively. UBA2 expression in gliomas correlated with World Health Organization (WHO) grade, IDH gene status, 1p19q deletion, histological type, and immune cell infiltration in glioma. UBA2 expression in carcinomas also correlated with drug sensitivity. KaplanMeier analysis revealed that high expression of UBA2 predicted poorer survival in glioma patients. A nomogram model containing UBA2 expression was constructed for clinical practice. Knockdown of UBA2 was observed to suppress glioma cell progression and sensitize glioma cells to irradiation in vitro. Conclusion: Overall, this research showed that UBA2 might be involved not only in the development of glioma but also in the regulation of immunity, drug sensitivity, and radiosensitivity. Therefore, UBA2 may be a potential target for therapy and a candidate biomarker for glioma diagnosis and prognosis.